TYTatsuhiro Yoshiki

Tatsuhiro Yoshiki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tatsuhiro Yoshiki has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Susumu Kageyama

    Department of Urology, Shiga University of Medical Science, Shiga, Japan

    4 shared publications
  • Takahiro Isono

    Central Research Laboratory, Shiga University of Medical Science, Shiga, Japan

    4 shared publications
  • Hideaki Iwaki

    Department of Urology, Shiga University of Medical Science, Shiga, Japan

    3 shared publications
  • Takeshi Yuasa

    Department of Transfusion Medicine and Cell Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan

    2 shared publications
  • Yusaku Okada

    Department of Urology, Shiga University of Medical Science, Tsukinowa, Seta, Otsu, Shiga 520‐2192

    2 shared publications
  • Akito Terai

    Department of Urology, Kurashiki Central Hospital, Miwa, Kurashiki, Okayama 710‐8602

    1 shared publication

Latest Publications

  • Up‐regulation of urinary UPIII mRNA levels in vesicoureteral reflux patients: Potential application as a screening test for vesicoureteral reflux

    by Hideaki Iwaki, Kazuyoshi Johnin, Susumu Kageyama, Chul Jang Kim, Takahiro Isono, Tatsuhiro Yoshiki

    Objectives:  Vesicoureteral reflux (VUR) is the most common congenital urinary tract anomaly. This disease can pose a major threat to the kidneys as twenty percent of patients with endstage renal disease are reported to have VUR. Although genetic studies for uroplakin III (UPIII) have been reported recently, no study has focused on UPIII gene expression in VUR patients. We describe here the up‐regulation of UPIII mRNA in exfoliated urinary cells from primary VUR patients.Methods:  A real‐time RT‐PCR for UPIII mRNA was performed on exfoliated urothelial cells from 18 primary VUR and 38 control samples. UPIII mRNA copies were calculated for each sample. The statistical differences were assessed by the Mann‐Whitney U test. Receiver operator characteristic curves were constructed for analysis of the diagnostic values.Results:  UPIII mRNA was found to be up‐regulated to a greater extent in VUR than in control exfoliated urinary cells (mean ± SE: 497.0 ± 178.5 copies vs. 69.0 ± 10.0 copies, respectively, P < 0.001). In evaluating the measurement of urinary UPIII mRNA as a screening test for VUR, the sensitivity was 77.8% and the specificity was 76.3% by the best diagnostic cutoff point.Conclusions:  This is the first report demonstrating up‐regulation of UPIII in mRNA levels in VUR patients. We submit that the quantitative measurement of urinary UPIII mRNA has a potential of developing into the first non‐invasive screening test for VUR.


  • A novel tumor‐related protein, C7orf24, identified by proteome differential display of bladder urothelial carcinoma

    by Susumu Kageyama, Hideaki Iwaki, Hirokazu Inoue, Takahiro Isono, Takeshi Yuasa, Masaki Nogawa, Taira Maekawa, Masamichi Ueda, Yoichiro Kajita, Osamu Ogawa, et al.

    Proteome analysis of bladder cancer with narrow‐range pH 2‐DE has identified a novel protein on chromosome 7 encoded by ORF 24 (C7orf24) as one of the highly expressed proteins in cancer cells. C7orf24 is currently registered in the protein database as a hypothetical protein with unknown function. The homologs of C7orf24 in other animals have also been registered as putative protein genes. Western blot analysis using a mAb against C7orf24 confirmed its higher expression in bladder cancer compared with normal tissue. Several other cancer cell lines were also found to express C7orf24. However, the introduction of C7orf24 into Rat‐1 or NIH3T3 cells did not cause malignant transformation. A stable transfectant of NIH3T3 cells with recombinant retrovirus vector was produced for a growth rate assay, and a higher growth rate was observed in C7orf24‐expressing cells compared with the controls. Six kinds of small interfering RNAs (siRNAs) were then produced, and C7orf24‐siRNA#5 showed a strong knockdown effect on protein expression and significant antiproliferative effects on cancer cell lines were demonstrated by the MTT assay. Therefore, C7orf24 may have an important role in cancer cell proliferation, and may be an appropriate therapeutic target molecule against cancer.


  • Open Access

    Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, γ‐synuclein, and catechol‐o‐methyltransferase) identified by proteomic analysis

    by Hideaki Iwaki, Susumu Kageyama, Takahiro Isono, Yoshihiko Wakabayashi, Yusaku Okada, Koji Yoshimura, Akito Terai, Yoichi Aral, Hiroshi Iwamura, Mutsushi Kawakita, et al.

    Using proteomic analysis, we previously identified calreticulin (CRT) as a potentially useful urinary marker for bladder cancer. Now, we have also identified γ‐synuclein (SNCG) and a soluble isoform of catechol‐o‐methyltransferase (s‐COMT) as novel candidates for tumor markers in bladder cancer, by means of proteomic analysis. In the process of establishing a superior tumor marker system, we investigated the diagnostic value of a combination assay of these three proteins. Voided urine samples were obtained from 112 bladder cancer and 230 control patients. Urinary CRT, SNCG, and s‐COMT were measured as a combined marker by quantitative western blot analysis. Relative concentration of each protein was calculated and the diagnostic value of a concomitant examination of these markers was evaluated by receiver operator characteristic analysis. With the best diagnostic cutoff, the overall sensitivity of the combined markers was 76.8% (95% confidence interval, 69–81%) with a specificity of 77.4% (72–80%), while those of a single use of CRT were 71.4% and 77.8%, respectively. When evaluated in relation to tumor characteristics, such as grade, stage, size, and outcome of urinary cytology, the diagnostic capacity of the combined markers was equal to or better than that of CRT in all categories. Concomitant use of CRT, SNCG, and s‐COMT had higher sensitivity for detection of bladder cancer than did single use of CRT. Our study suggests that use of this panel of markers will improve the diagnosis of bladder cancer and may allow the development of a protein microarray assay or multi‐channel enzyme‐linked immunosorbent assay.


  • High Expression of Human Uroplakin Ia in Urinary Bladder Transitional Cell Carcinoma

    by Susumu Kageyama, Tatsuhiro Yoshiki, Takahiro Isono, Tsutomu Tanaka, Choi Jang Kim, Takeshi Yuasa, Yusaku Okada

    Uroplakins (UPs) Ia, Ib, II, and III are tissue‐specific and differentiation‐dependent transmem‐brane proteins of the urothelium. We assessed the usefulness of human UP Ia as a histological marker by examining its expression in urinary bladder transitional cell carcinoma (TCC). A polyclonal antibody against human UP Ia was raised using a synthesized polypeptide. We applied our antibody to various organ tissues, including urothelium, and observed no crossreactivity. Analysis by RT‐PCR of normal urothelium, TCC and other organ tissues indicated that the human UP Ia gene expression is highly specialized to urothelium, and is conserved in TCC. Using immunohistochemistry, we investigated the expression of UP Ia in TCC from patients who had undergone radical cystectomy and from autopsy cases. Positive staining (10% or more positive cancer cells) was noted in primary lesions from 61 of 63 (96.8%) cystectomy patients. Depending on pathological grade, high expression (50% or more positive cancer cells) was observed in 17 of 18 (94.4%) moderately‐ to well‐differentiated TCC and in 36 of 45 (80.0%) poorly differentiated TCC. With regard to tumor invasion, high expression was noted in 20 of 22 (90.9%) superficial and 33 of 41 (80.5%) muscle‐invasive TCC. Cause‐specific survival rates were 68.6% and 75.0% in high‐ and low‐expression patients, respectively (log‐rank test, P=0.855, mean follow‐up; 65.0 months). In metastases, positive reactions were observed in 13 of 18 (72.2%) lesions. UP Ia may represent a specific histological marker judging from the stable expression, although its value as a prognostic factor remains undetermined.